The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010–2011

References

• Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME. Impact of antimicrobial multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti Infect Ther 2013;11:321–31.
   PubMed Web of Science ®Google Scholar
• Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008;6:751–63.
   PubMed Web of Science ®Google Scholar
• Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011;35:736–55.
   PubMed Web of Science ®Google Scholar
• Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO-SENS study revisited. Int J Antimicrob Agents 2012;39:45–51.
   PubMed Web of Science ®Google Scholar
• Gupta K, Trautner B. In the clinic. Urinary tract infection. Ann Intern Med 2012;156:ITC3-1–16.
   Google Scholar
• Marcos M, Soriano A, Iñurrieta A, Martínez JA, Romero A, Cobos N, et al. Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens. J Antimicrob Chemother 2011;66:2119–25.
   PubMed Web of Science ®Google Scholar
• Marra AR, Camargo LF, Pignatari AC, Sukiennik T, Behar PR, Medeiros EA, et al. Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study. J Clin Microbiol 2011;49:1866–71.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52–9.
   PubMed Web of Science ®Google Scholar
• Alsterlund R, Carlsson B, Gezelius L, Haeggman S, Olsson-Liljequist B. Multiresistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak. Scand J Infect Dis 2009;41:410–15.
   PubMed Web of Science ®Google Scholar
• Naseer U, Haldorsen B, Tofteland S, Hegstad K, Scheutz F, Simonsen GS, et al. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. APMIS 2009;117:526–36.
   PubMed Web of Science ®Google Scholar
• Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009;34:407–13.
   PubMed Web of Science ®Google Scholar
• de Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 2011;8:e1001104.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC; 2014. Available from: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf
   Google Scholar
• Tofteland S, Dahl KH, Aasnaes B, Sundsfjord A, Naseer U. A nationwide study of mechanisms conferring reduced susceptibility to extended-spectrum cephalosporins in clinical Escherichia coli and Klebsiella spp. isolates. Scand J Infect Dis 2012;44:927–33.
   PubMed Web of Science ®Google Scholar
• NORM/NORM-VET 2009. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo; 2010. ISSN:1502-2307 (print)/1890-9965 (electronic). Available from: www.antibiotikaresistens.no
   Google Scholar
• NORM/NORM-VET 2010. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo; 2011. ISSN:1502-2307 (print)/1890-9965 (electronic). Available from: www.antibiotikaresistens.no
   Google Scholar
• Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014;551:1–15.
   Google Scholar
• Bassetti M, Ginocchio F, Mikulska M. New treatment options against gram-negative organisms. Crit Care 2011;215:1–9.
   Google Scholar
• Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, et al. Effects of phenotype and genotype on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 2007;45:199–205.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Hope R, Fagan EJ, Warner M, Woodford N, Potz N. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England. J Antimicrob Chemother 2006;57:1012–14.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009;63:243–5.
   PubMed Web of Science ®Google Scholar
• Grude N, Tveten Y, Kristiansen BE. Urinary tract infections in Norway: bacterial etiology and susceptibility. A retrospective study of clinical isolates. Clin Microbiol Infect 2001;7:543–7.
   PubMed Web of Science ®Google Scholar
• Soraas A, Sundsfjord A, Jorgensen SB, Liestol K, Jenum PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One 2014;9:e85889.
   PubMed Web of Science ®Google Scholar
• Soraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae–a case-control study in a low prevalence country. PLoS One 2013;8:e69581.
   PubMed Web of Science ®Google Scholar
• Van Aken S, Lund N, Ahl J, Odenholt I, Tham J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia. Scand J Infect Dis 2014;46:753–62.
   PubMed Web of Science ®Google Scholar
• Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006;57:367–8.
   PubMed Web of Science ®Google Scholar
• NORM/NORM-VET 2013. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo; 2014. ISSN:1502-2307 (print)/1890-9965 (electronic). Available from: www.antibiotikaresistens.no
   Google Scholar
• Mulvey MR, Bryce E, Boyd DA, Ofner-Agostini M, Land AM, Simor AE, et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005;49:358–65.
   PubMed Web of Science ®Google Scholar
• Haldorsen B, Aasnaes B, Dahl KH, Hanssen AM, Simonsen GS, Walsh TR, et al. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 2008;62:694–702.
   PubMed Web of Science ®Google Scholar
• Haldorsen BC, Simonsen GS, Sundsfjord A, Samuelsen O. Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6')-Ib. Diagn Microbiol Infect Dis 2014;78:66–9.
   PubMed Web of Science ®Google Scholar
• Karah N, Poirel L, Bengtsson S, Sundqvist M, Kahlmeter G, Nordmann P, et al. Plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden. Diagn Microbiol Infect Dis 2010;66:425–31.
   PubMed Web of Science ®Google Scholar
• NORM/NORM-VET 2011. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo; 2012. ISSN:1502-2307 (print)/1890-9965 (electronic). Available from: www.antibiotikaresistens.no
   Google Scholar
• Brolund A, Edquist PJ, Makitalo B, Olsson-Liljequist B, Soderblom, Tegmark Wisell K, et al. Epidemiology of extended-spectrum β-lactamase-producing Escherichia coli in Sweden 2007-2011. Clin Microbiol Infect 2014;20:O344–352.
   PubMed Web of Science ®Google Scholar
• Ostholm-Balkhed A, Tarnberg M, Nilsson M, Johansson AV, Handberger H, Monstein HJ, et al. Prevalence of extended-spectrum β-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden. Scand J Infect Dis 2010;42:831–8.
   PubMed Web of Science ®Google Scholar
• Ostholm Balkhed A, Tarnberg M, Monstein HJ, Hallgren A, Hanberger H, Nilsson LE. High frequency of co-resistance in CTX-M-producing Escherichia coli to non-β-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden. Scand J Infect Dis 2013;45:271–8.
   PubMed Web of Science ®Google Scholar
• Bobenchik AM, Deak E, Hindler JA, Charlton CL, Humphries RM. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints. J Clin Microbiol 2015;53:816–23.
   PubMed Web of Science ®Google Scholar
• Munoz-Davila MJ, Roig M, Yague G, Blazquez A, Salvador C, Segovia M. Comparative evaluation of Vitek 2 identification and susceptibility testing of urinary tract pathogens directly and isolated from chromogenic media. Eur J Clin Microbiol Infect Dis 2013;32:773–80.
   PubMed Web of Science ®Google Scholar
• Rantakokko-Jalava K, Elo-Lehtonen E, Meurman O. Comparison of workflow and accuracy of identification and antimicrobial susceptibility testing of clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa and enterococci by Vitek 2 and routine methods. APMIS 2006;114:43–9.
   PubMed Web of Science ®Google Scholar
• Jakobsen L, Cattoir V, Jensen KS, Hammerum AM, Nordmann P, Frimodt-Moller N. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. J Antimicrob Chemother 2012;67:2438–44.
   PubMed Web of Science ®Google Scholar
• Marre R, Schulz E. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, OXA-1 and chromosomal β-lactamases. Arzneimittelforschung 1988;38:863–5.
   PubMed Web of Science ®Google Scholar
• Marrs EC, Day KM, Perry JD. In vitro activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase. J Antimicrob Chemother 2014;69:2873–5.
   PubMed Web of Science ®Google Scholar
• Neu HC. Penicillin-binding proteins and role of amdinocillin in causing bacterial cell death. Am J Med 1983;75:9–20.
   PubMed Web of Science ®Google Scholar
• Barry AL. Critical evaluation of amdinocillin disk susceptibility tests correlated with agar dilution tests. J Clin Microbiol 1986;23:983–5.
   PubMed Web of Science ®Google Scholar
• Patel TA, Dilley R, Williams A, Vanstone GL, Balakrishnan I. Comparison of the Phoenix automated system, the Etest method and broth microdilution in determining temocillin susceptibility of Enterobacteriaceae. J Antimicrob Chemother 2013;68:1685–6.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Villalobos H, Cardentey-Reyes A, Thiroux C, Nonhoff C, Struelens MJ. Comparison of four commercial methods for determining temocillin susceptibility of Escherichia coli. J Antimicrob Chemother 2009;63:832–4.
   PubMed Web of Science ®Google Scholar